000079139 001__ 79139
000079139 005__ 20210526094557.0
000079139 0247_ $$2doi$$a10.1016/j.trsl.2018.03.004
000079139 0248_ $$2sideral$$a106599
000079139 037__ $$aART-2018-106599
000079139 041__ $$aeng
000079139 100__ $$0(orcid)0000-0002-5748-6078$$aAlvarez-Arguedas, S.
000079139 245__ $$aTherapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer
000079139 260__ $$c2018
000079139 5060_ $$aAccess copy available to the general public$$fUnrestricted
000079139 5203_ $$aIntravesical instillation of bacillus Calmette-Guérin (BCG) has been a first-line therapy for non–muscle-invasive bladder cancer for the last 4 decades. However, this treatment causes serious adverse events in a significant number of patients and a substantial percentage of recurrence episodes. MTBVAC is a live-attenuated vaccine derived from a Mycobacterium tuberculosis clinical isolate and is currently under evaluation in clinical trials to replace BCG as a tuberculosis vaccine. Here, we describe for the first time the potential of MTBVAC as a bladder cancer therapy in vitro and in vivo in a preclinical model. MTBVAC colonized human bladder tumor cells to a much greater extent than BCG via a mechanism mediated by macropinocytosis and induced cell growth inhibition after internalization. In vivo testing in an orthotopic murine model of bladder cancer demonstrated a higher antitumor effect of MTBVAC in experimental conditions in which BCG did not work. Our data encourage further studies to support the possible application of MTBVAC as a new immunotherapeutic agent for bladder cancer.
000079139 536__ $$9info:eu-repo/grantAgreement/ES/DGA/FSE$$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P
000079139 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000079139 590__ $$a4.915$$b2018
000079139 591__ $$aMEDICAL LABORATORY TECHNOLOGY$$b2 / 29 = 0.069$$c2018$$dQ1$$eT1
000079139 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b22 / 135 = 0.163$$c2018$$dQ1$$eT1
000079139 591__ $$aMEDICINE, GENERAL & INTERNAL$$b19 / 159 = 0.119$$c2018$$dQ1$$eT1
000079139 592__ $$a1.803$$b2018
000079139 593__ $$aBiochemistry (medical)$$c2018$$dQ1
000079139 593__ $$aPublic Health, Environmental and Occupational Health$$c2018$$dQ1
000079139 593__ $$aPhysiology (medical)$$c2018$$dQ1
000079139 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000079139 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000079139 700__ $$0(orcid)0000-0001-7866-2803$$aUranga, S.$$uUniversidad de Zaragoza
000079139 700__ $$aMartín, M.
000079139 700__ $$aElizalde, J.
000079139 700__ $$0(orcid)0000-0002-9713-2127$$aGomez, A.B.$$uUniversidad de Zaragoza
000079139 700__ $$aJulián, E.
000079139 700__ $$aNardelli-Haefliger, D.
000079139 700__ $$0(orcid)0000-0003-2993-5478$$aMartín, C.$$uUniversidad de Zaragoza
000079139 700__ $$0(orcid)0000-0001-7897-9173$$aAguilo, N.$$uUniversidad de Zaragoza
000079139 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000079139 7102_ $$11008$$2X$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cProy. investigación HQA
000079139 773__ $$g197 (2018), 32-42$$pTransl. Res.$$tTranslational Research$$x1931-5244
000079139 8564_ $$s1051190$$uhttps://zaguan.unizar.es/record/79139/files/texto_completo.pdf$$yPostprint
000079139 8564_ $$s42716$$uhttps://zaguan.unizar.es/record/79139/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000079139 909CO $$ooai:zaguan.unizar.es:79139$$particulos$$pdriver
000079139 951__ $$a2021-05-26-09:31:33
000079139 980__ $$aARTICLE